Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and activ...
Key Highlights: Implications: GC Biopharma’s Hunterase IV (idursulfase) has now been approved in India (CDSCO) and Taiwan (TFDA), bringing the intravenous enzyme replacement ther...
Key Highlights: Implications: The USFDA’s EIR and VAI classification provide regulatory closure for Strides Pharma’s Bengaluru facility following the five observations issued during the May 2026 inspe...
Key Highlights: Implications: Optimus Pharma’s DCGI approval for Tapinarof Cream 1% gives India its first locally manufactured, non‑steroidal topical for adult plaque psoriasis, offering dermatologist...
Key Highlights: Implications: The approval broadens AstraZeneca’s trastuzumab deruxtecan franchise in India from later-line metastatic use into the earlier, potentially larger HER2-positiv...
Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Qdenga’s approval as India’s first dengue vaccine creates a new prevention market in a country where reported cases have risen about 11‑fold in two decad...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Recent Regulatory Developments India’s biopharmaceutical industry stands at an inflection point where its scientific capabilities and production scale are increasingly recognized globa...
Latest Developments in USFDA Inspections India plays a crucial role in the global pharmaceutical supply chain, supplying a large share of generic medicines to markets around the world. As Indian...
